P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

Bibliographic Details
Main Authors:	L. H. Sehn, K. Hübel, S. Luminari, A. Salar, B. E. Wahlin, A. K. Gopal, C. Bonnet, S. Paneesha, M. Trneny, H. Mashegu, C. Lihou, D. Li, C. W. Scholz
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847280.69256.81

Internet